PTO/SB/05 (03-01) .

Amino Derivatives of EM-138 and Methods of Treating Angiogenesis W

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION **TRANSMITTAL**

05213-0652 (43170-266942) Attorney Docket No. Inventors Robert J. D'Amato

(Only for new nonprovisional applications under 37 C.F.R. 1.53(b))

ess Mail Label No. El 910716815 US

	Apress Mail Eaber No. EE 9107 10010 00			
APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents.	ADDRESS Box Patent P.O. Box 23: Arlington, VA	A 22202		
1. See Transmittal Form (e.g., PTO/SB/17) (Submit an original and a duplicate for fee processing) 2. Applicant claims small entity status. See 37 CFR 1.27. 3. Specification (preferred arrangement set forth below) - Descriptive title of the Invention - Cross Reference to Related Applications - Statement Regarding Fed sponsored R & D - Reference to sequence listing, a table, or a computer program listing appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure	 7. □ CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix) 8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. □ Computer Readable Form (CRF) b. Specification Sequence Listing on: □ CD-ROM or CD-R (2 copies); or □ paper c. □ Statements verifying identity of above copies ACCOMPANYING APPLICATIONS PARTS 9. □ Assignment Papers (cover sheet & document(s)) 10. □ 37 C.F.R.§3.73(b) Statement □ Power of (when there is an assignee) Attorney 			
4. Drawing(s) (35 U.S.C.113) [Total Sheets 5] 5. Oath or Declaration [Total Pages 1] a. Newly executed (original or copy) b. Copy from a prior application (37 CFR 1.63 (d)) (for a continuation/divisional with Box 18 completed) i. DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b). 6. Application Data Sheet. See 37 CFR 1.76	11. ☐ English Translation Docur 12. ☐ Information Disclosure Statement (IDS)/PTO-144 13. ☐ Preliminary Amendment 14. ☐ Return Receipt Postcard ((Should be specifically ite.) 15. ☐ Certified Copy of Priority Is (if foreign priority is claim 16. ☐ Nonpublication Request u (b)(2)(B)(i). Applicant mustor its equivalent. 17. ☐ Other:	Copies of IDS 9 Citations MPEP 503) mized) Document(s) ed) under 35 U.S.C. 122		
18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: ☑ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No: 09 / 545.139 Prior application information: Examiner Goldberg, J. Recite complete dependency back to first parent application: See Addendum 1 For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.				
17. CORRESPON	IDENCE ADDRESS			
☑ Customer Number or Bar Code Label 23370 PATENTI TRADEMARK COPICE				
Name (Print/Type) Jeffery B. Arnold, Esq.	Registration No. (Attorney/Agent) 39,540			
Signature Signature	Date	December 19, 2001		
ATLLIB02# 65343.1				

ADDENDUM 1

This application is a continuation of U.S. Serial No. 09/545,139, filed on April 7, 2000, which is a divisional application of U.S. Serial No. 08/950,673, filed October 16, 1997, now U.S. Patent No. 6,071,948, which is a continuation application of U.S. Serial No. 08/468,792, filed June 6, 1995, now U.S. Patent No. 5,712,291, which is a continuation application of U.S. Serial No. 08/168,817, filed December 15, 1993, now U.S. Patent No. 5,629,327, which is a continuation-in-part of U.S. Serial No. 08/025,046, filed on March 1, 1993, now abandoned.

FEE TRANSMITTAL

Attorney Docket No.

05213-0652 (43170-266942)

This sheet accompanies a patent application transmittal for the following application:

Inventor(s):

Robert J. D'Amato

Filing Date:

Concurrently herewith

Title:

AMINO DERIVATIVES OF EM-138 AND METHODS OF TREATING

ANGIOGENESIS WITH SAME

The filing fee is calculated as shown below:

1. FILING FEE:

SMALL ENTITY

LARGE ENTITY

FOR:	FEE	FEE PAID	FEE	FEE PAID
UTILITY FILING FEE	\$370	370.00	\$740	
DESIGN FILING FEE	\$165		\$330	
PLANT FILING FEE	\$255		\$510	
REISSUE FILING FEE	\$370		\$740	
PROVISIONAL FILING FEE	\$80		\$160	
i aring	SUBTOTAL (1)	\$370.00		\$

CLAIMS:

SMALL ENTITY

LARGE ENTITY

FOR:	NO. FILED	NO. EXTRA	RATE	FEE	RATE	FEE
TOTAL CLAIMS	46 - 20 =	26	x 9 =	234.00	x 18 =	
INDEP. CLAIMS	2 - 3 =	0	x 42 =	0	x 84 =	
MULTIPLE D	EPENDENT CLAI	M PRESENTED	+140 =		+280 =	
Ī		SUE	BTOTAL (2)	\$234.00		\$

3 ADDITIONAL FEES:

SMALL ENTITY

LARGE ENTITY

FOR:	FEE	FEE PAID	FEE	FEE PAID
LATE FILING, FEE OR OATH	\$65		\$130	
NON-ENGLISH SPECIFICATION	\$130		\$130	
OTHER				
	SUBTOTAL (3)	\$0	,	\$

TOTAL FILING FEE: \$604.00

A check is enclosed for the total amount: \$604.00

Charge any additional fees required under 37 C.F.R. 1.16 or 1.17 to Deposit Account 11-0855.

KILPATRICK STOCKTON LLP

1100 Peachtree Street

Suite 2800

Atlanta, Georgia 30309-4530

Telephone: 404-815-6500

Lossell D. Amod Atomor for Amilian

Reg. No. 39,540

Date: December 19, 2001